Skip to main content

Table 3 Virological response observed in the study groups 24 weeks after the end of the treatment

From: Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial

Virological response

Group A1 (n = 72)

Group A2 (n = 71)

Group B (n = 67)

Sustained virological response n.(%)

60 (83)*

53(75)†

33 (49)

Non sustained virological response n.(%)

12 (17)

18 (25)

34 (51)‡

  1. *P < 0.001 compared with Group B
  2. † P < 0.01 compared with Group B
  3. ‡ P < 0.001 compared with Group A1. P < 0.01 compared with Group A2.